Neuland Laboratories · NSE: NEULANDLAB · BSE: 524558
Q4 FY24 results · Jan–Mar 2024
Neuland Laboratories reported revenue from operations of ₹385.01 crore (down 5.4% from Q4 FY23) and net profit of ₹67.56 crore (down 20.1% from Q4 FY23) for Q4 FY24 (Jan–Mar 2024), on a consolidated basis.
| Item | Q4 FY24 | Q4 FY23 | YoY | Q3 FY24 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 385.01 | 407.07 | −5.4% | 392.83 | −2.0% |
| Other income | 5.36 | 8.06 | −33.6% | 2.10 | +155.0% |
| Total income | 390.37 | 415.14 | −6.0% | 394.93 | −1.2% |
| Profit before tax | 92.20 | 110.16 | −16.3% | 104.48 | −11.8% |
| Net profit for the period | 67.56 | 84.54 | −20.1% | 81.39 | −17.0% |
| EPS, basic (₹) | 52.66 | 65.90 | −20.1% | 63.44 | −17.0% |
| Net margin (%) | 17.5 | 20.8 | 20.7 |
| Item | Q4 FY24 | Q4 FY23 | YoY | Q3 FY24 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 385.01 | 407.07 | −5.4% | 392.83 | −2.0% |
| Other income | 5.36 | 8.06 | −33.6% | 2.10 | +155.0% |
| Total income | 390.37 | 415.14 | −6.0% | 394.93 | −1.2% |
| Profit before tax | 92.08 | 110.02 | −16.3% | 103.78 | −11.3% |
| Net profit for the period | 67.61 | 84.51 | −20.0% | 80.70 | −16.2% |
| EPS, basic (₹) | 52.70 | 65.87 | −20.0% | 62.90 | −16.2% |
| Net margin (%) | 17.6 | 20.8 | 20.5 |
Consolidated
- Filed with BSE
- 11 May 2024, 11:09 IST
- Board meeting
- 10 May 2024
- Period
- 01 Jan 2024 to 31 Mar 2024
- Review status
- Audited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 11 May 2024, 11:09 IST
- Board meeting
- 10 May 2024
- Period
- 01 Jan 2024 to 31 Mar 2024
- Review status
- Audited
- Source
- XBRL filing on BSE